ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

TUBE INVESTMENTS-Focus on Exports

Biochem. with the Korean company Chong Kun Dang (CKD) for a $ 30 million project to manufacture Rifampicin a bulk drug used in anti-TB formulations, at Mahad in Maharashtra. Anti-TB drugs are the pharmaceutical division's second most important products (after anti-rheumatics, including market leader Voveran) CKD will have a majority stake in the new company, with Hindustan Ciba-Gcigy holding 41.2 percent and Ciba-Geigy, Basle, picking up 9.8 per cent. , Hindustan Ciba-Geigy, in association with British Ciba Composites and Naltech, the technology wing of National Aerospace Laboratory (NAL, is to set up the country's first commercial venture to manufacture composites. Composites are substances having high strength to weight ratio, and find use in the aircraft industry and space research laboratories and are last replacing alunimium on the strength of these attributes. The proposed venture will receive technological support from the British firm based Duxford. NAL will provide land and workshop while Hindustan Ciba Gergy will step in with the marketing support. The thrust will be to tap the emerging aircraft industry in the country and also the defence industries with a large part of production being earmarked for exports.

Dear Reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here

Back to Top